Genscript Biotech Valuation
Is G51 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of G51 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: G51 (€1.27) is trading below our estimate of fair value (€1.48)
Significantly Below Fair Value: G51 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for G51?
Key metric: As G51 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is G51's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | US$1.01b |
| Market Cap | US$2.92b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | -9.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does G51's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3x | ||
GXI Gerresheimer | 1.2x | 10.2% | €2.4b |
1SXP SCHOTT Pharma KGaA | 4.2x | 10.7% | €4.0b |
EVT Evotec | 2.2x | 12.1% | €1.7b |
SRT3 Sartorius | 4.3x | 9.3% | €13.1b |
G51 Genscript Biotech | 2.9x | 39.9% | €22.7b |
Price-To-Sales vs Peers: G51 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (3x).
Price to Sales Ratio vs Industry
How does G51's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: G51 is good value based on its Price-To-Sales Ratio (2.9x) compared to the European Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is G51's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 10.6x |
Price-To-Sales vs Fair Ratio: G51 is good value based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (10.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.27 | €2.85 +124.1% | 18.7% | €3.55 | €1.95 | n/a | 10 |
| Nov ’25 | €1.37 | €2.78 +102.8% | 18.7% | €3.46 | €1.91 | n/a | 10 |
| Oct ’25 | €1.58 | €2.70 +70.9% | 18.8% | €3.34 | €1.83 | n/a | 10 |
| Sep ’25 | €1.39 | €2.70 +94.2% | 18.8% | €3.34 | €1.83 | n/a | 10 |
| Aug ’25 | €1.41 | €2.86 +102.5% | 27.6% | €3.66 | €1.25 | n/a | 9 |
| Jul ’25 | €0.97 | €2.94 +203.5% | 27.4% | €3.88 | €1.25 | n/a | 10 |
| Jun ’25 | €1.17 | €3.27 +179.5% | 17.7% | €3.89 | €1.89 | n/a | 10 |
| May ’25 | €1.38 | €3.40 +146.2% | 10.6% | €3.89 | €2.71 | n/a | 10 |
| Apr ’25 | €1.75 | €3.40 +93.7% | 10.6% | €3.89 | €2.71 | n/a | 10 |
| Mar ’25 | €1.81 | €3.60 +99.4% | 5.4% | €3.89 | €3.19 | n/a | 10 |
| Feb ’25 | €1.61 | €3.60 +123.4% | 5.4% | €3.89 | €3.19 | n/a | 10 |
| Jan ’25 | €2.23 | €3.62 +62.9% | 6.7% | €4.07 | €3.16 | n/a | 10 |
| Dec ’24 | €2.49 | €3.63 +45.9% | 6.7% | €4.08 | €3.17 | n/a | 10 |
| Nov ’24 | €2.73 | €3.60 +31.7% | 12.3% | €4.20 | €2.89 | €1.37 | 9 |
| Oct ’24 | €2.44 | €3.46 +42.0% | 17.0% | €4.21 | €2.23 | €1.58 | 10 |
| Sep ’24 | €2.12 | €3.33 +57.2% | 16.8% | €4.09 | €2.16 | €1.39 | 10 |
| Aug ’24 | €2.29 | €3.41 +49.3% | 19.1% | €4.30 | €2.15 | €1.41 | 10 |
| Jul ’24 | €2.04 | €3.40 +66.4% | 19.0% | €4.30 | €2.15 | €0.97 | 10 |
| Jun ’24 | €2.07 | €3.38 +63.8% | 21.0% | €4.16 | €2.19 | €1.17 | 6 |
| May ’24 | €2.40 | €3.27 +36.2% | 22.8% | €4.10 | €2.16 | €1.38 | 5 |
| Apr ’24 | €1.95 | €3.71 +90.3% | 21.3% | €4.82 | €2.41 | €1.75 | 5 |
| Mar ’24 | €2.67 | €3.75 +40.3% | 21.3% | €4.87 | €2.43 | €1.81 | 5 |
| Feb ’24 | €3.23 | €3.72 +15.4% | 22.0% | €4.91 | €2.40 | €1.61 | 5 |
| Jan ’24 | €2.95 | €3.69 +25.1% | 24.6% | €5.00 | €2.44 | €2.23 | 4 |
| Dec ’23 | €2.39 | €3.78 +58.0% | 24.9% | €5.18 | €2.53 | €2.49 | 4 |
| Nov ’23 | €2.57 | €3.99 +55.3% | 28.6% | €5.44 | €2.65 | €2.73 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.1b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$701.80
7D
-8.9%
1Y
-4.9%
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.40
7D
1.7%
1Y
-8.9%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.38
7D
-0.5%
1Y
-0.4%